S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Healthia Limited (HLA.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$0.91
52-Week Range N/A
Volume155,400 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield1.27%
Healthia Limited provides health services in Australia. The company operates 72 podiatry clinics under the My FootDr brand; 23 physiotherapy clinics under the Allsports Physiotherapy brand; and 7 hand therapy clinics under the Extend Rehabilitation brand, as well as manufactures and sells 3D printed orthotic devices for podiatry clinics. It also sells podiatry and foot and nail care products, podiatry equipment, surgical instruments, orthotic materials, clinical consumables to podiatrists, hospitals, medical centres, nursing homes, and allied health professionals. The company was incorporated in 2018 and is based in Bowen Hills, Australia.


Overall MarketRank

0.67 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical Care Facilities
Phone61 7 3180 4900



Sales & Book Value

Annual Sales$87.23 million
Book ValueA$0.70 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive HLA News and Ratings via Email

Sign-up to receive the latest news and ratings for HLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Healthia Limited (HLA.AX) (ASX:HLA) Frequently Asked Questions

What stocks does MarketBeat like better than Healthia Limited (HLA.AX)?

Wall Street analysts have given Healthia Limited (HLA.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Healthia Limited (HLA.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How often does Healthia Limited (HLA.AX) pay dividends? What is the dividend yield for Healthia Limited (HLA.AX)?

Healthia Limited (HLA.AX) announced a Final dividend on Thursday, August 27th. Investors of record on Monday, September 28th will be given a dividend of 0.02 per share on Monday, September 28th. This represents a dividend yield of 1.98%. The ex-dividend date is Tuesday, September 8th.
View Healthia Limited (HLA.AX)'s dividend history

Is Healthia Limited (HLA.AX) a good dividend stock?

Healthia Limited (HLA.AX) pays an annual dividend of A$0.02 per share and currently has a dividend yield of 1.27%. The dividend payout ratio of Healthia Limited (HLA.AX) is 48.78%. This payout ratio is at a healthy, sustainable level, below 75%.
View Healthia Limited (HLA.AX)'s dividend history.

Who are some of Healthia Limited (HLA.AX)'s key competitors?

Who are Healthia Limited (HLA.AX)'s key executives?

Healthia Limited (HLA.AX)'s management team includes the following people:
  • Mr. Wesley James Coote, Group MD, CEO & Director
  • Mr. Christopher Banks, CFO & Company Sec.
  • Mr. Anthony Peter Ganter, Group COO & Exec. Director
  • Mr. Dean Hartley, Chief Technology Officer
  • Mr. Darren Lindsey Stewart, Director of Podiatry & Exec. Director
  • Dr. Kerrie Evans, Group Chief Education & Research Officer

What is Healthia Limited (HLA.AX)'s stock symbol?

Healthia Limited (HLA.AX) trades on the ASX under the ticker symbol "HLA."

How big of a company is Healthia Limited (HLA.AX)?

Healthia Limited (HLA.AX) has a market capitalization of $0.00 and generates $87.23 million in revenue each year.

What is Healthia Limited (HLA.AX)'s official website?

The official website for Healthia Limited (HLA.AX) is www.healthia.com.au.

How can I contact Healthia Limited (HLA.AX)?

The company can be reached via phone at 61 7 3180 4900.

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.